Licensing Agreement with Samyang Biopharm
Bio-Synectics licensed out its oral anticancer drug to Samyang Biopharmaceuticals Corporation - Maeil Business Newspaper-
Samyang Biopharmaceuticals Corporation signed the licensing agreement with Bio-Synectics for commercializing of an incrementally modified drug of Bio-Synectics.
The drug is a targeted anticancer drug manufactured by Bio-Synectics’ NUFS nanotechnology. Its indications are liver cancer, thyroid cancer, and kidney cancer.
NUFS nanotechnology allows the decrease of dosage by increasing the bioavailability of the drug.
Currently, preclinical studies of the drug have been finished. Samyang Biopharmaceuticals Corporation will take charge of the clinical trial, drug approval, and commercialization of the drug by its contract with Bio-Synectics.
[Published 15. January, 2018]
Samyang Biopharmaceuticals Corp. is a pharmaceutical company that was established in 2011 following the separation of the pharmaceutical business of Samyang. Samyang Biopharmaceuticals Corp.'s pharmaceutical business is one of the three major growth drivers of the Samyang Group, along with the chemical and food businesses. Since its entry into the pharmaceutical business in 1995, Samyang Biopharmaceuticals Corp. has invested more than 20% of its annual sales in its pursuit of innovative R&D. In doing so, Samyang Biopharmaceuticals Corp. is engaged in new medical technology and pharmaceuticals, such as the drug delivery system (DDS), and are currently developing and conducting sales of anticancer drugs, Genexol® and Nanoxel® M, a smoking cessation patch, Nicostop®, and biodegradable surgical sutures, Trisorb® and Monosorb®.